ImmunoGen Inc reports results for the quarter ended in March - Earnings Summary

ImmunoGen

28/04/2023 14:32

* ImmunoGen Inc  IMGN.OQ  reported a quarterly adjusted loss
of 16
cents​​ per share for the quarter ended in March. The mean
expectation of twelve analysts for the quarter was for a loss
of 25 cents per share.
    * Revenue rose 31% to $49.87 million from a year ago;
analysts
expected $20.47 million. 
    * ImmunoGen Inc's reported EPS for the quarter was a loss
of 16
cents​.
    * The mean earnings estimate of analysts had risen by
about 12.4%
in the last three months.​ 
    * In the last 30 days, there have been no negative revisions
of
earnings estimates 
    * ImmunoGen Inc shares had risen by 12.5% this quarter and
lost 12.9% so far this year.
    * The company reported a quarterly loss of $41.01 million.
    * Wall Street's median 12-month price target for ImmunoGen
Inc is
$12.00 
    * The current average analyst rating on the shares is "buy"
and
the breakdown of recommendations is 9 "strong buy" or "buy," 3
"hold" and no "sell" or "strong sell." 

This summary was machine generated from LSEG Refinitiv data
April 28 at 01:31 p.m. UTC. ​All figures in US dollars unless
otherwise stated. QUARTER ENDING    ESTIMATE       ACTUAL         BEAT, MET,
                                                 MISSED
 Mar. 31 2023      -0.25          -0.16          Beat
 Dec. 31 2022      -0.30          -0.23          Beat
 Sep. 30 2022      -0.25          -0.31          Missed
 Jun. 30 2022      -0.21          -0.24          Missed